Self-Selection for Statin Appears Safe, Effective
(MedPage Today) -- ATLANTA -- The vast majority of people correctly identified their own need for a statin using a web tool and took the drug appropriately without a prescription, according to an actual use study, supporting the safety of approval... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 8, 2024 Category: Cardiology Source Type: news
With Ticagrelor, Aspirin May Not Be Needed After PCI for Acute Coronary Syndrome
(MedPage Today) -- ATLANTA -- In select patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndromes who were event-free for 1 month on dual antiplatelet therapy (DAPT), treatment with ticagrelor (Brilinta) alone... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 8, 2024 Category: Cardiology Source Type: news
Dollars, Points Help CV Patients Increase Activity Dollars, Points Help CV Patients Increase Activity
Modest financial incentives and gamification encouraged people with cardiovascular risks to meaningfully increase daily step counts over 18 months, in the BE ACTIVE trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 8, 2024 Category: Cardiology Tags: Cardiology Source Type: news
Coronary Sinus Implant Proves Symptom Relief Benefit in Refractory Angina
(MedPage Today) -- ATLANTA -- For people with stable coronary artery disease and refractory angina, a coronary sinus reducer (CSR) implant showed a symptom alleviation benefit in the small placebo-controlled ORBITA-COSMIC trial.
The number of... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 8, 2024 Category: Cardiology Source Type: news
Apolipoprotein A1 Infusions After Acute MI Disappoint in Phase III Trial
(MedPage Today) -- ATLANTA -- Plasma-derived human apolipoprotein A1 (CSL112) infusions failed to improve outcomes for acute myocardial infarction (MI) patients with multivessel coronary artery disease and other cardiovascular risk factors, the... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 8, 2024 Category: Cardiology Source Type: news
Medicare Can Cover Anti-Obesity Drugs for Heart Disease -- But at What Cost?
(MedPage Today) -- On March 8, 2024, FDA approved Wegovy (semaglutide) to treat cardiovascular disease risks -- heart attack, stroke, and death -- for obese or overweight adults with a history of cardiovascular disease, making it the first... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 8, 2024 Category: Primary Care Source Type: news
Beta-Blockers Fail to Deliver Secondary Prevention Benefit in Key MI Patients
(MedPage Today) -- ATLANTA -- Beta-blockers had no additive benefit over contemporary therapies for people with acute myocardial infarction (MI) maintaining a preserved left ventricular ejection fraction (LVEF), the REDUCE-AMI randomized trial... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 8, 2024 Category: Cardiology Source Type: news
Antisense Drug Slashes High Triglycerides
(MedPage Today) -- ATLANTA -- A novel antisense mRNA drug slashed triglycerides in higher risk or moderate hypertriglyceridemia patients and in those with extremely elevated levels from familial chylomicronemia syndrome, two randomized phase... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 8, 2024 Category: Cardiology Source Type: news
Self-Expanding Evolut Valves Edge Out Sapien in Majority-Female TAVR Trial
(MedPage Today) -- ATLANTA -- For transcatheter aortic valve replacement (TAVR) candidates with a small aortic annulus, the two leading platforms offered differing hemodynamic valve performances despite being similarly effective at 1 year, according... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 8, 2024 Category: Cardiology Source Type: news
Wegovy Helps HFpEF Patients With Diabetes Mellitus
(MedPage Today) -- ATLANTA -- Weight loss and heart failure benefits with semaglutide (Wegovy) extended to patients with obesity-related heart failure with preserved ejection fraction (HFpEF) who have type 2 diabetes, the STEP-HFpEF DM trial showed... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 7, 2024 Category: Cardiology Source Type: news
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension
The KARDIA-2 study met its primary endpoint demonstrating additive, placebo-adjusted systolic blood pressure reductions of up to 12.1 mmHgat month three. These results were statistically significant and clinically meaningfulZilebesiran demonstrated an encouraging safety and tolerability profile when added to standard of care antihypertensives Basel, 7 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam today released detailed results from the Phase II KARDIA-2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care (SOC) antihypertensives. T...
Source: Roche Investor Update - April 7, 2024 Category: Pharmaceuticals Source Type: news
Proof of Benefit in Acute MI Again Evades an SGLT2 Inhibitor
(MedPage Today) -- ATLANTA -- The SGLT2 inhibitor empagliflozin (Jardiance) did not exactly prevent deaths and heart failure (HF) events when initiated atop other standard therapies for acute myocardial infarction (MI), the EMPACT-HF trial found... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 7, 2024 Category: Cardiology Source Type: news
Interatrial Shunt's Prospects in Heart Failure Shrink After RELIEVE-HF
(MedPage Today) -- ATLANTA -- An interatrial shunt failed to provide a clinical benefit to people with heart failure (HF) overall in the RELIEVE-HF trial, though actual harm or benefit seemed to hinge on the patient's left ventricular ejection... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 7, 2024 Category: Cardiology Source Type: news
New REDUCE-IT ® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results Published Simultaneously in the Journal of the American College of Cardiology (JACC) – DUBLIN, Ireland and BRIDGEWATER, N.J., April 06, 2024 (GLOBE NEWSWIRE) --…#baselinehigh #ldlclevels #dublin #ireland #bridgewater #vascepa #lipoproteina #jacc #nabilabadir #mb (Source: Reuters: Health)
Source: Reuters: Health - April 6, 2024 Category: Consumer Health News Source Type: news
Short-term incentives for exercise can lead to sustained increases in activity
NIH-supported study shows certain perks can spur long-term behavior change in adults with cardiovascular disease risks (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - April 5, 2024 Category: American Health Source Type: news
